A recent retrospective study published in the ound that atrial fibrillation (AF) occurred for the first time in 16 of 30 patients (53%) of patients with implantable devices being followed at the center conducting the study. Journal of Cardiovascular Electrophysiology f
Of the patients experiencing AF for the first time, 14 of 16 (88%) of the patients were not aware of having experienced any clinical symptoms. As patients age, AF appears to be a common consequence of HCM. Patients may be caught unaware and unprepared, so monitoring is especially important.
According to a
recent study published June 20 in the Journal of the American College of Cardiology, more than 1/3 of patients in atrial fibrillation are not receiving sufficient anti-coagulation. Many of these patients are receiving only aspirin instead of a more effective blood thinner like warfarin, or one of the newer anti-coagulant drugs like Pradaxa or Xarelto.
In the April edition of the American Journal of Cardiology, Italian HCM experts published their findings which indicate that an individual patient’s
HCM causing gene does not influence chances of developing atrial fibrillation and shouldn’t influence the management strategies for the condition.